Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CRX 150

Drug Profile

CRX 150

Alternative Names: Amoxapine/dipyridamole; CRx-150; Dipyridamole/amoxapine

Latest Information Update: 02 Jul 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CombinatoRx
  • Class Anti-inflammatories; Anti-ischaemics; Antiplatelets; Antirheumatics; Chemoprotectants; Dibenzoxazepines; Ischaemic heart disorder therapies; Piperazines; Pyrimidines; Tricyclic antidepressants; Vasodilators
  • Mechanism of Action Cytokine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Periodontal disorders; Rheumatoid arthritis

Most Recent Events

  • 02 Jul 2007 Interim results from a phase II clinical trial in patients with rheumatoid arthritis added to the adverse events and Rheumatic Disease therapeutic trials sections
  • 29 Jun 2007 Discontinued - Phase-II for Periodontal disorders in Estonia (PO)
  • 29 Jun 2007 Discontinued - Phase-II for Periodontal disorders in Norway (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top